Should I buy or sell Ayala Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ADXS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXS, but not buy additional shares or sell existing shares. View ADXS analyst ratings or view top-rated stocks .

How have ADXS shares performed in 2024?

Ayala Pharmaceuticals' stock was trading at $0.6670 at the beginning of the year. Since then, ADXS shares have decreased by 14.5% and is now trading at $0.57. View the best growth stocks for 2024 here .

When is Ayala Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our ADXS earnings forecast .

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) released its earnings results on Thursday, September, 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $0.25 million for the quarter.

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO) , Madrigal Pharmaceuticals (MDGL) , Merck & Co., Inc. (MRK) , Anavex Life Sciences (AVXL) , Vistagen Therapeutics (VTGN) , Novavax (NVAX) , Highpower International (HPJ) , OPKO Health (OPK) and Athersys (ATHX) .

How do I buy shares of Ayala Pharmaceuticals?

Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ADXS

Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis

→ The Next Nvidia? (From InvestorPlace) (Ad)

Free ADXS Stock Alerts

$0.57

-0.08 (-12.31%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.50
▼
$0.57
50-Day Range: $0.59
▼
$1.15
52-Week Range: $0.50
▼
$1.95

Volume: 9,468 shs
Average Volume: 21,878 shs
Market Capitalization: $6.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines SEC Filings Social Media

Get Ayala Pharmaceuticals alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Ayala Pharmaceuticals Stock (NASDAQ:ADXS)

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

ADXS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ADXS Stock News Headlines

April 16, 2024 | americanbankingnews.com

StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

April 8, 2024 | americanbankingnews.com

Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 2, 2024 | seekingalpha.com

Immunome: An Oncology Powerhouse In The Making

March 26, 2024 | globenewswire.com

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

March 16, 2024 | finance.yahoo.com

IMNM Oct 2024 22.500 call

March 16, 2024 | finance.yahoo.com

IMNM Oct 2024 25.000 call

March 16, 2024 | finance.yahoo.com

IMNM Oct 2024 25.000 put

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 16, 2024 | finance.yahoo.com

IMNM Oct 2024 45.000 call

February 20, 2024 | businesswire.com

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

February 10, 2024 | msn.com

Advaxis Executes Strategic Unregistered Equity Sales

February 7, 2024 | msn.com

Advaxis Announces Definitive Agreement with Ayala Pharmaceuticals

February 6, 2024 | msn.com

Immunome to buy AL102, a phase 3 asset for treatment of desmoid tumors

February 6, 2024 | finance.yahoo.com

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

November 24, 2023 | morningstar.com

Ayala Pharmaceuticals Inc Ordinary Shares ADXS

November 20, 2023 | sfgate.com

Ayala Pharmaceuticals: Fiscal Q4 Earnings Snapshot

November 17, 2023 | msn.com

Ladenburg Thalmann Downgrades Ayala Pharmaceuticals (ADXS)

October 23, 2023 | finance.yahoo.com

Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023

October 19, 2023 | finance.yahoo.com

Ayala Pharmaceuticals Announces Closing of Merger with Biosight

August 10, 2023 | finance.yahoo.com

Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

August 3, 2023 | investing.com

Ayala Pharmaceuticals Inc (ADXS)

August 1, 2023 | finance.yahoo.com

Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023

July 27, 2023 | finance.yahoo.com

Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement

July 5, 2023 | finance.yahoo.com

Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors

June 5, 2023 | finance.yahoo.com

Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023 | finance.yahoo.com

Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

See More Headlines

Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 9/09/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/21/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ADXS
CUSIP: N/A
CIK: 1100397
Web: www.ayalapharma.com
Phone: 609-452-9813
Fax: 609-452-9818
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($7.98)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: -210,876.91%
Return on Equity: -2,798.92%
Return on Assets: -195.41%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.53
Quick Ratio: 0.53

Sales & Book Value

Annual Sales: $10,000.00
Price / Sales: 612.75
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.61) per share
Price / Book: -0.93

Miscellaneous

Outstanding Shares: 10,750,000
Free Float: 10,684,000
Market Cap: $6.13 million
Optionable: Not Optionable
Beta: 1.62

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Dr. Ruth Ben Yakar Ph.D. (Age 54)
Chief Exec. Officer
Dr. Stela Gangrenovitch Ph.D.
Co-Founder, Chief Scientist Officer and Director
Mr. Mark Gengrinovitch LLB
Co-Founder, Chief Financial Officer and Director

Key Competitors

View All Competitors

ADXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Ayala Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ADXS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXS, but not buy additional shares or sell existing shares.
View ADXS analyst ratings or view top-rated stocks.
How have ADXS shares performed in 2024?: Ayala Pharmaceuticals' stock was trading at $0.6670 at the beginning of the year. Since then, ADXS shares have decreased by 14.5% and is now trading at $0.57.
View the best growth stocks for 2024 here.
When is Ayala Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our ADXS earnings forecast.
How were Ayala Pharmaceuticals' earnings last quarter?: Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) released its earnings results on Thursday, September, 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $0.25 million for the quarter.

What other stocks do shareholders of Ayala Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), Vistagen Therapeutics (VTGN), Novavax (NVAX), Highpower International (HPJ), OPKO Health (OPK) and Athersys (ATHX).
How do I buy shares of Ayala Pharmaceuticals?: Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADXS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis

About Ayala Pharmaceuticals Stock (NASDAQ:ADXS)

ADXS Stock Price History

ADXS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ADXS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info